AtriCure, Inc. (NASDAQ:ATRC – Get Free Report) Director Regina Groves sold 5,313 shares of the firm’s stock in a transaction on Friday, September 11th. The stock was sold at an average price of $54.22, for a total value of $288,070.86. Following the transaction, the director directly owned 34,546 shares of the company’s stock, valued at $1,873,084.12. The trade was a 13.33% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.
AtriCure Price Performance
Shares of NASDAQ:ATRC traded up $1.25 on Monday, hitting $55.79. The company had a trading volume of 1,154,686 shares, compared to its average volume of 809,532. The company has a current ratio of 4.22, a quick ratio of 3.19 and a debt-to-equity ratio of 0.14. AtriCure, Inc. has a 52-week low of $25.36 and a 52-week high of $56.02. The business has a 50 day moving average of $42.41 and a 200 day moving average of $33.56. The company has a market cap of $2.84 billion, a PE ratio of 265.68 and a beta of 1.26.
AtriCure (NASDAQ:ATRC – Get Free Report) last posted its quarterly earnings data on Thursday, July 23rd. The medical device company reported $0.18 EPS for the quarter. AtriCure had a return on equity of 2.34% and a net margin of 1.85%.The firm had revenue of $153.60 million during the quarter, compared to analysts’ expectations of $151.80 million. During the same quarter last year, the business posted ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. As a group, equities analysts anticipate that AtriCure, Inc. will post 0.29 earnings per share for the current fiscal year.
Institutional Investors Weigh In On AtriCure
Wall Street Analysts Forecast Growth
ATRC has been the subject of a number of analyst reports. Raymond James Financial set a $52.00 price objective on shares of AtriCure in a research report on Tuesday, July 21st. BTIG Research boosted their price target on AtriCure from $45.00 to $55.00 and gave the company a “buy” rating in a report on Monday, August 24th. UBS Group reduced their price target on AtriCure from $55.00 to $50.00 and set a “buy” rating on the stock in a research note on Tuesday, July 28th. Needham & Company LLC raised their price objective on AtriCure from $45.00 to $64.00 and gave the stock a “buy” rating in a report on Wednesday, September 2nd. Finally, Piper Sandler lifted their price objective on AtriCure from $50.00 to $60.00 and gave the company an “overweight” rating in a research report on Thursday, August 27th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $52.00.
View Our Latest Stock Analysis on ATRC
AtriCure Company Profile
AtriCure, Inc (NASDAQ: ATRC) is a medical device company focused on the treatment of atrial fibrillation (AF) and related conditions. The company develops, manufactures and sells surgical and minimally invasive technologies designed to restore normal heart rhythm and reduce the risk of stroke associated with AF.
Its product portfolio includes the AtriClip system for excluding the left atrial appendage, the Isolator and Synergy systems for surgical ablation, and the cryoICE system, which uses cryothermal energy in cardiac procedures.
Featured Articles
- Five stocks we like better than AtriCure
- Analysts Are Punting Their Calls Into the Next Quarter After Adobe’s Mixed Earnings
- Institutional Money Is Pouring Into These 2 Altcoin ETFs
- The End of Big Tech Buybacks? Only One Hyperscaler Is Still Repurchasing Shares
- 3 Dividend Kings to Buy While They’re Still Beaten Down
Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.
